NewBiologix Licenses Florabio’s HEK293 Cell Line for the Generation of Novel and Proprietary Cell Lines for the Stable Expression of rAAVs used in Gene Therapy
NewBiologix’s innovative approach stands to replace the industry-standard transient transfection methods, offering a stable, more reliable, and scalable solution for biopharmaceutical companies developing gene therapies.
- NewBiologix’s innovative approach stands to replace the industry-standard transient transfection methods, offering a stable, more reliable, and scalable solution for biopharmaceutical companies developing gene therapies.
- Under the terms of the agreement, NewBiologix acquired rights to use Florabio’s HEK293 suspension cell line for research and commercial applications.
- Leveraging proprietary genomic data, NewBiologix plans to engineer the Florabio HEK293 cell line and select highly characterized clones with exceptional growth, expansion, and transfectability properties.
- NewBiologix will achieve its goals faster and more efficiently by starting with the 'FlorabioHEK293' cell line and our chemically defined HEK293 medium.”